Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cerebrospinal fluid xenin levels during body mass reduction: no evidence for obesity-associated defective transport across the blood–brain barrier

Abstract

Context:

Recent studies have shown that xenin can act in the hypothalamus, reducing food intake through a leptin- and melanocortin system-independent mechanism.

Objective:

To evaluate the impact of body mass reduction on the blood and cerebrospinal fluid (CSF) levels of xenin.

Design and setting:

Thirteen obese patients (11 women) selected for roux-in-Y gastric bypass surgery were evaluated before and approximately 8 months after surgery. Xenin was determined in serum and CSF by radioimmunoassay.

Results:

As compared with lean subjects, obese patients have increased blood levels of xenin, which reduce after surgery. There are significant correlations between blood xenin and blood leptin and insulin levels. CSF concentration of xenin is 10-fold lower than blood levels, and is significantly higher in obese subjects as compared with lean ones, returning to normal levels after body mass reduction. There is a significant linear correlation between CSF and blood levels of xenin.

Conclusion:

Xenin is present in the human CSF in a concentration 10-fold lower than the blood. Both blood and CSF xenin are correlated with blood levels of important markers of adiposity, leptin and insulin. The levels of CSF xenin are linearly correlated with blood xenin, independently of patient body mass, suggesting that either its transport across the blood–brain barrier is not saturated in the concentration range detected in this study or that there is a coordinated release of xenin from the periphery and the CNS.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Feurle GE, Hamscher G, Kusiek R, Meyer HE, Metzger JW . Identification of xenin, a xenopsin-related peptide, in the human gastric mucosa and its effect on exocrine pancreatic secretion. J Biol Chem 1992; 267: 22305–22309.

    CAS  PubMed  Google Scholar 

  2. Hamscher G, Meyer HE, Metzger JW, Feurle GE . Distribution, formation, and molecular forms of the peptide xenin in various mammals. Peptides 1995; 16: 791–797.

    Article  CAS  Google Scholar 

  3. Alexiou C, Zimmermann JP, Schick RR, Schusdziarra V . Xenin—a novel suppressor of food intake in rats. Brain Res 1998; 800: 294–299.

    Article  CAS  Google Scholar 

  4. Cline MA, Nandar W, Rogers JO . Xenin reduces feed intake by activating the ventromedial hypothalamus and influences gastrointestinal transit rate in chicks. Behav. Brain Res 2007; 179: 28–32.

    CAS  Google Scholar 

  5. Leckstrom A, Kim ER, Wong D, Mizuno TM . Xenin a gastrointestinal peptide, regulates feeding independent of the melanocortin signaling pathway. Diabetes 2009; 58: 87–94.

    Article  CAS  Google Scholar 

  6. Cooke JH, Patterson M, Patel SR, Smith KL, Ghatei MA, Bloom SR et al. Peripheral and central administration of xenin and neurotensin suppress food intake in rodents. Obesity (Silver Spring) 2009; 17: 1135–1143.

    CAS  Google Scholar 

  7. Velloso LA, Schwartz MW . Altered hypothalamic function in diet-induced obesity. Int J Obes 2011; 35: 1455–1465.

    Article  CAS  Google Scholar 

  8. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568–1575.

    Article  CAS  Google Scholar 

  9. Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, Farid AR, Smith FJ, Campfield LA . Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000; 85: 4003–4009.

    Article  CAS  Google Scholar 

  10. Banks WA, DiPalma CR, Farrell CL . Impaired transport of leptin across the blood-brain barrier in obesity. Peptides 1999; 20: 1341–1345.

    Article  CAS  Google Scholar 

  11. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348: 159–161.

    Article  CAS  Google Scholar 

  12. El-Haschimi K, Pierroz DD, Hileman SM, Bjørbaek C, Flier JS . Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest 2000; 105: 1827–1832.

    Article  CAS  Google Scholar 

  13. Gastrointestinal surgery for severe obesity. National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 1992; 55(2 Suppl): 615S–619S.

    Google Scholar 

  14. de Carvalho CP, Marin DM, de Souza AL, Pareja JC, Chaim EA, de Barros Mazon S et al. GLP-1 and adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism. Obes Surg 2009; 19: 313–320.

    Article  Google Scholar 

  15. Field BCT, Chaudhri OB, Bloom SR . Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol 2010; 6: 444–453.

    Article  CAS  Google Scholar 

  16. Woods SC, D’Alessio DA . Central control of body weight and appetite. J Clin Endocrinol Metab 2008; 93(11 Suppl 1): S37–S50.

    Article  CAS  Google Scholar 

  17. Neumiller JJ. . Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin Ther 2011; 33: 528–576.

    Article  CAS  Google Scholar 

  18. Coll AP, Farooqi IS, Challis BG, Yeo GSH, O’Rahilly S . Proopiomelanocortin and energy balance: insights from human and murine genetics. J Clin Endocrinol Metab 2004; 89: 2557–2562.

    Article  CAS  Google Scholar 

  19. Kim ER, Mizuno TM . Xenin delays gastric emptying rate and activates the brainstem in mice. Neurosci Lett 2010; 481: 59–63.

    Article  CAS  Google Scholar 

  20. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941–948.

    Article  CAS  Google Scholar 

  21. Adam TCM, Westerterp-Plantenga MS . Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects. Br J Nutr 2005; 93: 845–851.

    Article  CAS  Google Scholar 

  22. le Roux CW, Aylwin SJB, Batterham RL, Borg CM, Coyle F, Prasad V et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243: 108–114.

    Article  Google Scholar 

Download references

Acknowledgements

Grants for this work were provided by Fundaçao de Amparo a Pesquisa do Estado de Sao Paulo.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L A Velloso.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van de Sande-Lee, S., Cardoso, A., Garlipp, C. et al. Cerebrospinal fluid xenin levels during body mass reduction: no evidence for obesity-associated defective transport across the blood–brain barrier. Int J Obes 37, 416–419 (2013). https://doi.org/10.1038/ijo.2012.70

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijo.2012.70

Keywords

This article is cited by

Search

Quick links